~~<i id='6159F8CBD5'><strike id='6159F8CBD5'><tt id='6159F8CBD5'><pre id='6159F8CBD5'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

hotspot

author：focus 2025-10-02 03:24:15 - browse：381

HHS 2020 — PhRMA is suing the Biden administration over its new Medicare drug price negotiation program. Graeme Sloan/Sipa USA

WASHINGTON — After losing the drug pricing fight on Capitol Hill, PhRMA is taking its battle to the courts.

The pharmaceutical industry’s biggest lobbying group on Wednesday filed a long-expected lawsuit challenging Democrats’ drug pricing law that allowed Medicare to start negotiating prices for certain medicines.

PhRMA joins a growing club of companies and trades challenging the law. Merck, Bristol Myers Squibb, and the Chamber of Commerce have already filed similar suits in different courts.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Continuity nursing helped my family in our darkest PICU moments
Next article： The Pandemic Treaty must support building strong health systems

focus

hotspot

knowledge

Wikipedia

ChrisBoshoff,farright,speakingatapanelwith,fromleft,MatthewHerperofSTAT,KenKeller,LeviGarraway,andSu

WSS

Scientists grapple with ethics of stem cell research

A woman pleads guilty to fire that kept a Wyoming abortion clinic from opening for a year

Cord blood banking comes at a high cost to babies

How to increase colonoscopy rates? Looks like an AI can help

Caribou posts encouraging results on off

US jobless claims fall again as labor market continues to flash strength

hotspot

hotspot

focus

Tori Bowie and the unacceptable rates of Black maternal death

At ASCO, pharma leaders speak of advances in 'smart bomb' drugs

Dobbs anniversary: the lost opportunity of abortion as health care

Readout LOUD podcast: ASCO preview, a Duchenne trial failure

BioMarin wins approval for gene therapy to treat hemophilia A

Delta passengers in Vegas fall sick while waiting on flight in triple

Medicare details structure of new drug price negotiation program

ASCO Daily Recap: Safety data from Novartis, survival from Pfizer

Psychedelics group wrestles with new pharma identity

Headers linked to memory issues, raising questions about soccer safety as the World Cup kicks off

focus

There’s a way to spot data fakery. All journals should be using it

Cord blood banking comes at a high cost to babies

Scientists grapple with ethics of stem cell research

This biotech could one day make human eggs from scratch. But first, they’re trying to rethink IVF

See how much Covid

Are infertility treatments 'essential' during the Covid

focus

hotspot

knowledge

Wikipedia